CompanySK Biopharmaceuticals Co., Ltd.
South Korea
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders.
Private/Public:
public
Phone:031-8093-0114
Fax:031-8093-0000
Email:[email protected]
Website:http://www.skbp.com/eng.do
Address:221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, South Korea
2011
Since
1
Country
3
Top Service Categories
34
Sub-Service Categories
API/Biologicals Production
API/Biologics development and manufacturing
Reagents/excipients manufactured
Discovery and Preclinical
Chemistry/Discovery Tech./In silico services
Efficacy In Vitro
In vivo animal models
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing Facilities | Room 309, 866 Halei Road, Zhangjiang High Tech Park, Shanghai | 86-(21)-5080-4990 | Shanghai | 86-(21)-5000-3483 | China | ||||||
| Manufacturing Facilities | 461 From Road, 5th Floor, Paramus, NJ 07652 | 1-201-421-3864 | Paramus | 1-973-227-4488 | United States of America | NJ-New Jersey | |||||
| Global Corporate Headquarters | 221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494 | 031-8093-0114 | Gyeonggi-do | 031-8093-0000 | South Korea | ||||||
| 99, Seorin-dong, Jongro-gu, Seoul, 110-110 | 82-2-2121-0110 | Seoul | 82-2-2121-5333 | South Korea |
- (22.Jun.2022) Long-Term Efficacy and Safety Data of XCOPRI (Cenobamate Tablets) CV Published in Neurology
- (25.May.2022) SK Biopharmaceuticals Announces Social Value Performance for 2021
- (19.May.2022) SK Biopharmaceuticals to Invest in US Digital Therapy Firm
- (12.May.2022) SK Biopharmaceuticals' Revenue Plunges 70% in Q1
- (20.Apr.2022) Trials of SK Biopharm, HanAll Biopharma Disrupted by Shanghai Lockdown
- (14.Apr.2022) Ubix Therapeutics, SK Biopharmaceuticals Enter Into Research Collaboration Agreement to Develop Novel Therapeutics Based on Targeted Protein Degradation
- (31.Mar.2022) SK Life Science Presents Long-Term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI (Cenobamate Tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting
- (28.Mar.2022) Axsome Therapeutics to Acquire Sunosi From Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience
- (24.Mar.2022) SK Biopharmaceutical to Double Performance in All Business Areas
- (24.Feb.2022) SK Biopharm Soon to Begin Phase 3 Cenobamate Trial in Asia
- (24.Feb.2022) SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative
- (13.Jan.2022) SK Life Science Announces FDA Clearance of IND Application for Its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
- (06.Jan.2022) SK Life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
- (06.Jan.2022) SK Biopharmaceuticals Starts P3 Trials of YKP509 on Applying for IND
- (04.Jan.2022) BIORCHESTRA, SK Biopharmaceuticals Collaborate to Develop miRNA-targeted Therapeutics
- (23.Dec.2021) Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI (Cenobamate) in Canada
- (03.Dec.2021) SK Life Science Presents Long-Term Data of XCOPRI (Cenobamate Tablets) CV in Adults With Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting
- (18.Nov.2021) National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for Jazz Pharmaceuticals' Sunosi (Solriamfetol) for the Treatment of Adults With Excessive Daytime Sleepiness (EDS) Caused by Narcolepsy
- (12.Nov.2021) SK Biopharmaceuticals Out-Licensed Six Clinical Compounds to Ignis
- (12.Oct.2021) Epilepsia Publishes Two Post-Hoc Analyses From Long-Term Study of XCOPRI (Cenobamate Tablets) CV
- (07.Oct.2021) SK Biopharm Set to Expand Epilepsy Drug's Indications
- (31.Aug.2021) Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi (Solriamfetol) for Excessive Daytime Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea
- (02.Aug.2021) SK Life Science, Inc. Launches STEPS Toward Zero Movement to Educate, Inspire and Activate the Epilepsy Community
- (20.Jul.2021) Long-Term Safety and Tolerability of XCOPRI (Cenobamate Tablets) CV Published in Epilepsia
- (02.Jul.2021) SK Biopharm Aims to Be Global Top-10 Health Firm by 2030